Patrick Dolezal
Stock Analyst at LifeSci Capital
(4.27)
# 1,334
Out of 4,417 analysts
179
Total ratings
40.9%
Success rate
11.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick Dolezal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMX Immix Biopharma | Initiated Coverage: Buy | $19 | $9.13 | +108.11% | 1 | Jun 17, 2026 | |
| MBX MBX Biosciences | Maintained: Buy | $91 | $41.59 | +118.80% | 5 | Jun 13, 2026 | |
| NGNE Neurogene | Maintained: Buy | $60 | $30.79 | +94.87% | 8 | Jun 8, 2026 | |
| OCS Oculis Holding AG | Maintained: Buy | $45 | $11.30 | +298.23% | 9 | Jun 6, 2026 | |
| SLGL Sol-Gel Technologies | Maintained: Buy | $184 | $70.36 | +161.51% | 2 | May 28, 2026 | |
| IBIO iBio, Inc. | Maintained: Buy | $5 | $1.60 | +212.50% | 11 | May 16, 2026 | |
| RCKT Rocket Pharmaceuticals | Rated: Buy | $12 | $3.16 | +279.75% | 44 | May 9, 2026 | |
| KOD Kodiak Sciences | Rated: Buy | $70 → $65 | $35.71 | +82.02% | 8 | May 9, 2026 | |
| SRZN Surrozen | Rated: Buy | $37 → $44 | $23.97 | +83.56% | 5 | May 9, 2026 | |
| GPCR Structure Therapeutics | Rated: Buy | $107 → $104 | $45.00 | +131.11% | 12 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 | $62.55 | n/a | 21 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $0.6316 | n/a | 25 | Nov 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 | $3.54 | n/a | 12 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $0.7115 | n/a | 5 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $32.93 | n/a | 1 | Dec 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 → $25 | $3.53 | n/a | 2 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €10.00 → €25.00 | $3.12 | n/a | 8 | Jun 16, 2020 |
Immix Biopharma
Jun 17, 2026
Initiated Coverage: Buy
Price Target: $19
Current: $9.13
Upside: +108.11%
MBX Biosciences
Jun 13, 2026
Maintained: Buy
Price Target: $91
Current: $41.59
Upside: +118.80%
Neurogene
Jun 8, 2026
Maintained: Buy
Price Target: $60
Current: $30.79
Upside: +94.87%
Oculis Holding AG
Jun 6, 2026
Maintained: Buy
Price Target: $45
Current: $11.30
Upside: +298.23%
Sol-Gel Technologies
May 28, 2026
Maintained: Buy
Price Target: $184
Current: $70.36
Upside: +161.51%
iBio, Inc.
May 16, 2026
Maintained: Buy
Price Target: $5
Current: $1.60
Upside: +212.50%
Rocket Pharmaceuticals
May 9, 2026
Rated: Buy
Price Target: $12
Current: $3.16
Upside: +279.75%
Kodiak Sciences
May 9, 2026
Rated: Buy
Price Target: $70 → $65
Current: $35.71
Upside: +82.02%
Surrozen
May 9, 2026
Rated: Buy
Price Target: $37 → $44
Current: $23.97
Upside: +83.56%
Structure Therapeutics
May 9, 2026
Rated: Buy
Price Target: $107 → $104
Current: $45.00
Upside: +131.11%
Dec 11, 2023
Rated: Buy
Price Target: $60
Current: $62.55
Upside: n/a
Nov 11, 2023
Maintained: Buy
Price Target: $6
Current: $0.6316
Upside: n/a
Aug 10, 2023
Rated: Buy
Price Target: $14
Current: $3.54
Upside: n/a
Mar 9, 2023
Maintained: Buy
Price Target: $17 → $16
Current: $0.7115
Upside: n/a
Dec 11, 2022
Maintained: Buy
Price Target: $39
Current: $32.93
Upside: n/a
Mar 8, 2021
Maintained: Buy
Price Target: $27 → $25
Current: $3.53
Upside: n/a
Jun 16, 2020
Reiterated: Buy
Price Target: €10.00 → €25.00
Current: $3.12
Upside: n/a